Publications by authors named "D Fackrell"
Article Synopsis
- The long-term survival rates for patients with node negative gastric cancer after surgery are unclear, especially with the emergence of neoadjuvant chemotherapy.
- A study analyzed data from patients who received neoadjuvant chemotherapy followed by surgical resection to compare survival rates between those who received adjuvant chemotherapy and those who did not.
- Results showed that patients receiving adjuvant chemotherapy had a median survival of 150 months compared to 125 months for those who did not, indicating a statistically significant survival benefit that warrants further investigation.
Background: The evidence assessing the additional benefits of adjuvant chemotherapy (AC) following neoadjuvant therapy (NAT; i.e. chemotherapy or chemoradiotherapy) and oesophagectomy for oesophageal adenocarcinoma (EAC) are limited.
View Article and Find Full Text PDFPurpose: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices.
Methods: A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC.
Medical Student-led Outpatient Clinics: Improving Undergraduate Oncology Education.
Clin Oncol (R Coll Radiol)
July 2017